Collaboration and Teaming Day Sample Clauses

Collaboration and Teaming Day for collaboration and team work aimed at addressing the 51 Comprehensive School Improvement Plan (CSIP). Such work shall include but not be limited 52 to: CSIP development/review, collaborative assessment of student work, professional 1 development, short/long range planning, curriculum development and/or alignment, grade 2 level meetings, IEP collaboration, vertical teaming, and/or study groups.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Collaboration and Teaming Day for collaboration and team work aimed at addressing the 42 CSIP Plan. Such work may include but not be limited to: CSIP development/review, 43 collaborative assessment of student work, professional development, short/long range 44 planning, curriculum development and/or alignment, grade level meetings, IEP collaboration, 45 vertical teaming, and/or study groups. At a minimum, half of the time will be used for 46 implementation of this work by grade level or department team
Sample 1Sample 2
Collaboration and Teaming Day for collaboration and team work aimed at addressing the 48 Comprehensive School Improvement Plan. Such work may include but not be limited to: 49 CSIP development/review, collaborative assessment of student work, professional 50 development, short/long range planning, curriculum development and/or alignment, grade 51 level meetings, job-alike meetings, vertical teaming, and/or study groups. At a minimum, 1 half of the time will be used for implementation of this work by grade level or department
Sample 1
Collaboration and Teaming Day. For collaboration and team work aimed at addressing the Comprehensive School Improvement Plan. The work on these days will be facilitated by the building CSIP team with input from the staff. Such work may include but not be limited to: Collaborative assessment of student work, professional development, short/long range planning, curriculum development and/or alignment, grade level meetings, job-alike meetings, vertical teaming, and/or study groups. At a minimum, half of the time will be used for implementation of this work. A tentative plan for Collaboration and Teaming Days will be presented to the staff for input by October 31.
Sample 1

Related to Collaboration and Teaming Day

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Team Teaching Unit members participating in team teaching assignments will receive formula hour credit in proportion to the percentage of in-class involvement. When team-taught class sizes exceed the normal, the formula conditions specified in Section 4.3.3 shall apply.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research, Science and Technology Cooperation 1. The aims of cooperation in research, science and technology, carried out in the mutual interest of the Parties and in compliance with their policies, will be: (a) to build on existing agreements already in place for cooperation on research, science and technology; (b) to encourage, where appropriate, government agencies, research institutions, universities, private companies and other research organizations in the Parties to conclude direct arrangements in support of cooperative activities, programs or projects within the framework of this Agreement, specially related to trade and commerce; and (c) to focus cooperative activities towards sectors where mutual and complementary interests exist, with special emphasis on information and communication technologies and software development to facilitate trade between the Parties. 2. The Parties will encourage and facilitate, as appropriate, the following activities including, but not limited to:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Joint Network Implementation and Grooming Process Upon request of either Party, the Parties shall jointly develop an implementation and grooming process (the “Joint Grooming Process” or “Joint Process”) which may define and detail, inter alia:

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

Time is Money Join Law Insider Premium to draft better contracts faster.